+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Murine strain differences in hemostasis and thrombosis and tissue factor pathway inhibitor



Murine strain differences in hemostasis and thrombosis and tissue factor pathway inhibitor



Thrombosis Research 125(1): 84-89



Differences among murine strains often lead to differential responses in models of human disease. The aim of the current study was to investigate whether differences exist among strains in models of hemostasis and thrombosis and whether these differences are reflected in differences in the tissue factor (TF) pathway. We examined baseline hemostatic parameters and the response to FeCl3-induced arterial thrombosis and a tail vein bleeding model in C57BL/6J (C57), 129S1/SvImJ (129S), and Balb/cJ (BalbC) mice. Finally, we examined TF and tissue factor pathway inhibitor (TFPI) activities in blood and expression in vascular tissue to determine whether these factors covary with a thrombotic phenotype. No differences were observed in PT or aPTT among strains. 129S mice had lower platelet counts (p<0.001). BalbC had an increased rate of occlusion (mean occlusion time of 330+/-45 sec) in a FeCl(3)-induced model of thrombosis when compared to C57 (1182+/-349 sec) or 129 S (1442+/-281 sec) (p<0.05). Similarly, BalbC demonstrated reduced blood loss in tail bleeding experiments when compared to C57 and 129S. Vascular expression of TF and TFPI content did not correlate with the thrombotic phenotype of BalbC. However, circulating TFPI activities were lower in BalbC compared to both C57 and 129S mice. When normalized to circulating TF activities, BalbC had lower circulating TFPI activity than C57 and 129S, and there was a significant correlation between tail bleeding and normalized TFPI activity (r=0.67). These data suggest that there are significant differences among strains in thrombosis and hemostasis and that circulating TFPI activity correlates with these differences.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054508752

Download citation: RISBibTeXText

PMID: 19398123

DOI: 10.1016/j.thromres.2009.03.006


Related references

Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis. Blood 116(10): 1787-1794, 2010

The effect of vascular smooth muscle cell-targeted expression of tissue factor pathway inhibitor in a murine model of arterial thrombosis. Thrombosis and Haemostasis 92(3): 495-502, 2004

Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium. Blood 104(5): 1344-1349, 2004

Enoxaparin (E) and warfarin (W) differentially regulate tissue factor (TF), tissue factor pathway inhibitor (TFPI) and thrombin activatable fibrinolytic inhibitor (TAFI) in cancer patients with thrombosis. Journal of Clinical Oncology 23(16_Suppl): 2057-2057, 2016

A balance between tissue factor and tissue factor pathway inhibitor is required for embryonic development and hemostasis in adult mice. Blood 105(7): 2777-2782, 2005

Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: measurement of their levels in coagulation assays. Seminars in Thrombosis and Hemostasis 36(7): 764-771, 2011

Tissue factor and tissue factor pathway inhibitor levels in trophoblast cells: implications for placental hemostasis. Thrombosis and Haemostasis 92(4): 776-786, 2004

Gene targeting in hemostasis. tissue factor pathway inhibitor. Frontiers in Bioscience 6: D216-D221, 2001

Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk. Thrombosis Research 132(5): 627-634, 2013

Role of bone marrow derived tissue factor pathway inhibitor on hemostasis. Circulation 104(17 Suppl.): II 204, 2001

The importance of the binding of factor Xa to phospholipids in the inhibitory mechanism of tissue factor pathway inhibitor: the transmembrane and cytoplasmic domains of tissue factor are not essential for the inhibitory action of tissue factor pathway inhibitor. Thrombosis and Haemostasis 77(3): 492-497, 1997

Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. On behalf of the Subcommittee on Tissue factor Pathway Inhibitor (TFPI) of the Scientific and Standardization Committee of the ISTH. Thrombosis and Haemostasis 73(5): 873-875, 1995

Tissue factor pathway inhibitor in thrombosis and beyond. Methods in Molecular Medicine 93: 133-155, 2004

Differences in free and total tissue factor pathway inhibitor, and tissue factor in peripheral artery disease compared to healthy controls. Atherosclerosis 152(1): 29-34, 2000

Role of tissue factor pathway inhibitor as a natural inhibitor of intravascular thrombus formation in a rabbit model of carotid artery thrombosis. Circulation 92(8 Suppl. ): I486, 1995